Search Results for: FCER1G

93 interactions involving FCER1G - Fc epsilon receptor Ig found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Novel Symbol Description Pathways Hide Drugs Hide Diseases Hide
DGAT2L6 diacylglycerol O-acyltransferase 2 like 6
  • Acyl chain remodeling of DAG and TAG
EBP EBP cholestenol delta-isomerase
  • Cholesterol biosynthesis via desmosterol
  • Cholesterol biosynthesis via lathosterol
  • Tamoxifen
FA2H fatty acid 2-hydroxylase
  • Sphingolipid de novo biosynthesis
FAM209A family with sequence similarity 209 member A
FAXDC2 fatty acid hydroxylase domain containing 2
FCER1A Fc epsilon receptor Ia
  • Fc epsilon receptor (FCERI) signaling
  • Fc epsilon receptor (FCERI) signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated NF-kB activation
  • Omalizumab
  • Benzylpenicilloyl polylysine
  • TNX-901
FCGR3A Fc gamma receptor IIIa
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • FCGR activation
  • FCGR activation
  • Regulation of actin dynamics for phagocytic cup formation
  • Role of phospholipids in phagocytosis
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Cetuximab
  • Etanercept
  • Human immunoglobulin G
  • Gemtuzumab ozogamicin
  • Alemtuzumab
  • Alefacept
  • Palivizumab
  • Daclizumab
  • Bevacizumab
  • Catumaxomab
  • Sarilumab
  • Benralizumab
  • Amivantamab
  • NK cell defects, including the following disease: CD16 deficiency
  • Systemic lupus erythematosus
FFAR2 free fatty acid receptor 2
  • G alpha (q) signalling events
  • Free fatty acid receptors
  • GLPG-0974
FUNDC2 FUN14 domain containing 2
FXYD6 FXYD domain containing ion transport regulator 6
  • Ion homeostasis
  • Ion transport by P-type ATPases
  • Potential therapeutics for SARS
GIMAP5 GTPase, IMAP family member 5
GJA5 gap junction protein alpha 5
  • Gap junction assembly
  • Atrial fibrillation
GP6 glycoprotein VI platelet
  • GPVI-mediated activation cascade
  • Cell surface interactions at the vascular wall
  • Platelet Adhesion to exposed collagen
GPR61 G protein-coupled receptor 61
IER3IP1 immediate early response 3 interacting protein 1
KCNA1 potassium voltage-gated channel subfamily A member 1
  • Voltage gated Potassium channels
  • Enflurane
  • Amitriptyline
  • Isoflurane
  • Methoxyflurane
  • Promethazine
  • Miconazole
  • Desflurane
  • Dalfampridine
  • Tetraethylammonium
  • Amifampridine
  • Episodic ataxias
KCNN3 potassium calcium-activated channel subfamily N member 3
  • Ca2+ activated K+ channels
  • Procaine
  • Ritodrine
  • Nitrendipine
  • Miconazole
  • Colforsin
  • Dequalinium
  • Trimebutine
  • Rimtuzalcap
KIR2DL4 killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 4
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
LEPROTL1 leptin receptor overlapping transcript like 1
LMNA lamin A/C
  • XBP1(S) activates chaperone genes
  • Signaling by BRAF and RAF1 fusions
  • Mandibuloacral dysplasia
  • Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
  • Emery-Dreifuss muscular dystrophy
  • Dilated cardiomyopathy (DCM)
  • Limb-girdle muscular dystrophy (LGMD)
  • Hutchinson-Gilford progeria syndrome
  • Restrictive dermopathy
  • Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
  • Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy

Page 2 out of 5 pages